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Intravascular Optical Imaging Technology for
Investigating the Coronary Artery
Melissa J. Suter, PHD,*† Seemantini K. Nadkarni, PHD,*‡ Giora Weisz, MD,§
Atsushi Tanaka, MD, PHD,*‡ Farouc A. Jaffer, MD, PHD,* Brett E. Bouma, PHD,*‡¶
uillermo J. Tearney, MD, PHD*¶#
Boston and Cambridge, Massachusetts; and New York, New York
There is an ever-increasing demand for new imagingmethods that can provide additional information about
the coronarywall tobetter characterize and stratify high-riskplaques, and toguide interventional andpharma-
cologicmanagement of patientswith coronary artery disease.While there are a number of imagingmodalities
that facilitate the assessment of coronary artery pathology, this review paper focuses on intravascular optical
imagingmodalities that provide information on themicrostructural, compositional, biochemical, biomechani-
cal, and molecular features of coronary lesions and stents. The optical imaging modalities discussed include
angioscopy, optical coherence tomography, polarization sensitive-optical coherence tomography, laser
speckle imaging, near-infrared spectroscopy, time-resolved laser induced fluorescence spectroscopy, Raman
spectroscopy, and near-infrared fluorescence molecular imaging. Given the wealth of information that these
techniques can provide, optical imaging modalities are poised to play an increasingly significant role in the
evaluation of the coronary artery in the future. (J Am Coll Cardiol Img 2011;4:1022–39) © 2011 by the
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conespite widespread efforts toward its de-
tection and treatment, acute cardiovas-
cular events are still the leading cause of
death in the Western world (1). The
rupture of an unstable coronary atherosclerotic
plaque frequently precedes a majority of acute
cardiovascular events (2,3). The strong association
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1023There is compelling evidence suggesting that the
mechanisms intrinsic to coronary lesions that lead
to acute thrombosis are multi-factorial, involving a
complex interplay between structural, composi-
tional, biochemical, biomechanical, cellular, and
molecular processes in the vessel wall, as well as
complex humoral factors. Autopsy studies suggest
the typical hallmarks of the majority of unstable
plaques are the presence of a thin fibrous cap, a
large compliant necrotic core, and activated macro-
phages near the fibrous cap (4,5). Plaque instability
is influenced by the proteolysis of fibrous cap
collagen by matrix metalloproteinases released by
activated macrophages and apoptosis of intimal
smooth muscle cells (SMC), which impede collagen
synthesis (6–8). Mediated by endothelial produc-
tion of nitric oxide, transforming growth factor-,
nd plasmin, this dynamic imbalance between col-
agen synthesis and degradation causes a net reduc-
ion in collagen content and a mechanical weaken-
ng of the fibrous cap (9). A recent study suggests
hat increased collagenase expression yields thinner
ollagen fibers with disorganized fiber orientation,
hich may be associated with decreased mechanical
tability (10). Finite element studies have suggested
hat rupture of the fibrous cap is greatly affected by
egions of high biomechanical stress (11–13). The
orphology and mechanical properties of the ath-
roma affect stress distributions, (14,15), and plaque
upture frequently occurs in focal regions of high
tress concentrations caused by large differences in
he intrinsic mechanical properties of the fibrous
ap and lipid pool (5,11,15–17). The cumulative
ffect of these multiple factors compromises the
echanical stability of the plaque, resulting in an
levated risk of rupture (11,18,19). Since multiple
actors are involved in the process of atherogenesis
eading to plaque rupture, diagnostic techniques
hat provide synergistic information on these mul-
iple determinants may be required to prospectively
etect unstable or “vulnerable” coronary plaques.
Coronary stenting during percutaneous coronary
ntervention (PCI) has become the standard of care
or symptomatic and flow-limiting coronary artery
isease. Bare-metal stents (BMS) diminish the
lastic recoil of angioplasty to maintain lumen
atency, but have been limited by restenosis caused
y aggressive neointimal hyperplasia, therefore re-
uiring repeat PCI in a significant proportion of
atients. Although recently introduced drug-eluting
tents (DES) have mitigated restenosis by inhibiting
mooth-muscle cell proliferation, therapy of coronary
esions by current DES is accompanied by the need ior extended dual antiplatelet therapy regimens to
void late stent thrombosis (20–23). As a result, there
s substantial interest in developing ways to assess stent
ealing in vivo to guide the intensity and duration of
he pharmacological management of patients who
ere treated with DES as well as to evaluate next-
eneration platforms, like stents that promote re-
ndothelialization, and bioabsorbable stents.
Intravascular optical diagnostic techniques have
rovided new options for the evaluation of the
arious factors associated with atherosclerosis,
laque stability, and treatment of coronary artery
isease. These diagnostic techniques mea-
ure one or more of the processes that
ccur when the light interacts with the
issue including the reflectance, refraction,
cattering, or absorption and re-emission
f the incident light (Fig. 1). Angioscopy
llows direct visualization of the luminal
rtery surface (24); optical coherence to-
ography (OCT) provides high-
esolution cross-sectional images of plaque
icroarchitecture (25), stent placement
26–28), apposition (26,29–31), and strut
overage (32–36); polarization sensitive
PS)-OCT provides a measure of tissue
irefringence that may be related to colla-
en and SMC content (37); laser speckle
maging (LSI) (38) allows the evaluation
f biomechanical factors; optical spectro-
copic techniques provide methods to
valuate biochemical factors related to
laque stability (39); and near-infrared
uorescence (NIRF) opens up the possi-
ility of labeling and identifying individual
olecules within the artery wall (40). At-
ractive properties of optical imaging modal-
ties are that they are nondestructive, they
re amenable to implementation using flex-
ble small diameter fiber-optic catheters, and
hey may potentially be combined to allow
imultaneous measurements of the multiple types of
laque features (41,42). These optical imaging cathe-
ers can be easily used in the clinical management of
atients during coronary angiography and percutane-
us intervention.
Other review articles have summarized many of
he common imaging modalities used for evaluating
oronary arteries, covering a combination of intra-
ascular approaches such as intravascular ultra-
onography (IVUS) and optical imaging tech-
iques, and external to the body techniques
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1024tomography, and positron emission tomography
(43–52). This review, however, focuses on all major
intravascular optical imaging modalities. While
these optical imaging modalities have been in de-
velopment for years, many have recently undergone
significant technical improvements, as outlined in
this review. Furthermore, some of these intracoro-
nary imaging modalities have recently become, or
are becoming, commercially available and have
received approval by the Food and Drug Adminis-
tration (FDA) for human use. In this paper, we
provide an overview of all of the current intravas-
cular optical imaging modalities, we compare and
contrast the tissue properties measured by each
technique, and provide a critical review of each of
the imaging modalities in terms of potential current
and future clinical utility.
Angioscopy
The oldest optical imaging technique employed for
investigating the coronary arteries is angioscopy
(24). Angioscopy is an endoscopic imaging modal-
ity that allows direct visualization of the internal
surface of the coronary artery and consists of a white
light source, a flexible optical fiber bundle consist-
ing of separate illumination fibers that guide light
to, and collection fibers that collect the light re-
flected from the artery wall, and a distal lens at the
tip of the catheter to form an image with a large
field of view. Studies have demonstrated that an-
Figure 1. Schematic Diagram
The diagram shows the predominant light/tissue interactions that a
discussed in this review. LSI  laser speckle imaging; NIRF  near-i
cal coherence tomography; OFDI  optical frequency domain imag
ﬂuorescence spectroscopy.gioscopy can be used to differentiate arterial wallcomposition (53), including the detection of fibrous
or lipid-rich plaques, plaque disruptions, thrombi,
and ulcerations, to assess plaque vulnerability (54–
56), the response to treatment therapies (57,58),
and to evaluate stenting procedures including stent
placement, and neointimal coverage of individual
stent struts (59,60) (Fig. 2). While angioscopy has
been demonstrated to detect plaques and thrombi
that may be missed by angiography, to provide an
indication of the plaque composition through quan-
titative color analysis (61), and to evaluate the
effectiveness of coronary stenting procedures, an-
gioscopy is restricted to imaging surface morphol-
ogy. Although angioscopy is a commercially avail-
able FDA-approved optical imaging technology
that has been available for many years, its use in the
United States has been largely restricted to research
applications rather than clinical practice. Limita-
tions to the technology include the requirement to
clear the coronary lumen of blood with the infusion
of saline, the large catheter diameter that limits the
evaluation to proximal segments, the inability to
pass significant lesions, and the difficulties associ-
ated with accurate interpretation of the images,
which therefore mandate expertise. Angioscopy is
limited to surface and clot morphology, and adds
little insight on deep plaque composition. In rou-
tine clinical use in the United States, there are no
indications for angioscopy, and therefore, at pres-
ent, the use of angioscopy is restricted to research in
etected in each of the intravascular optical imaging modalities
red ﬂuorescence; NIRS  near-infrared spectroscopy; OCT  opti-
PS  polarization sensitive; TR-LIFS  time-resolved laser-inducedre d
nfra
ing;highly specialized centers.
y of
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1025Optical Coherence Tomography
OCT is a high-resolution (10 m axial; 20 to 40
m lateral resolution) imaging modality that gen-
erates cross-sectional images of tissue microstruc-
ture to penetration depths approaching 2 mm (62).
The underlying concept of OCT is similar to that
of ultrasonography; by measuring the delay time of
optical echoes reflected from subsurface structures
in biological tissues, structural information can be
obtained (Fig 1). Because of the high speed of light
propagation in tissue, the time delay of the return-
ing light is measured using low-coherence
interferometry.
There are 2 types of OCT, the first generation,
called time domain (TD)-OCT (62,63) that has
been used in patients from 2000 to the present, and
second-generation frequency domain (FD)-OCT
(64,65), also known as optical frequency domain
imaging (OFDI) (66,67), which has advantages
that currently make it the preferred technique in
interventional cardiology. In TD-OCT systems, a
broadband light source is split into a reference arm,
directed onto a mirror, and a sample arm that directs the
light into the artery wall. When the distance trav-
elled by the light in each arm of the interferometer
is within the coherence length of the source, the
returning light, once recombined, will form an
interference pattern. The amplitude of the detected
interference pattern is subsequently mapped to a
pixel intensity value corresponding to the discrete
axial location, or depth, within the tissue. To
Figure 2. Angioscopy Images Obtained From a Patient In Vivo
(A) An example of a nondisrupted glistening yellow plaque with no
low plaque after rupture and subsequent clot formation: mixed thr
cotton like or ragged appearance and presents fragmentation. Yello
protruding into lumen, which may be the mixture of thrombus and
image of an acute coronary syndrome culprit lesion. Figure courtesgenerate image information for an entire axial depthprofile, the reference mirror is translated, altering
the optical path length of the reference arm, and
hence the imaging depth inside the sample. Sys-
tematic scanning of the imaging beam across the
tissue can be performed to build 2-dimensional and
3-dimensional images. For FD-OCT/OFDI,
rather than utilizing a broadband light source and a
mechanically translating reference arm, interference
is generated using a rapidly tuned wavelength swept
source and a stationary reference arm (66). Each
frequency component of the detected interference
signal is associated with a discrete depth location
within the tissue. To generate an A-line, a tech-
nique called the Fourier transform converts the
interference information to depth resolved reflec-
tance (66).
TD-OCT has been used to image microstruc-
tural features of the artery wall in a number of
post-mortem studies where the image data can be
directly correlated to histopathology, the gold stan-
dard (25,68–73). These studies document the de-
velopment and validation of image criteria for
detecting features that correspond to tissue micro-
structures with high sensitivity and specificity. The
detected microstructural features (Fig. 3) include
macrophages (69,72), cholesterol crystals (25,71),
red and white thrombus (74,75), calcium deposits
(70,73), fibrous plaques (70,73), and lipid-rich
plaques (70,73,76). Yabushita et al. (73) reported
sensitivities and specificities of 71% to 79% and
97% to 98% for the detection of fibrous plaques,
95% to 96% and 97% for fibrocalcific plaques, and
dence of red or white thrombus on the plaque surface. (B) A yel-
us of white and red color is observed on the surface, which has
aterial detected in the thrombus has an irregular surface and is
d content from the necrotic core. This is a typical angioscopic
Yasunori Ueda.evi
omb
w m
lipi90% to 94% and 90% to 92% for lipid-rich plaques
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1026(73). These studies have provided the foundation
necessary for the interpretation of intracoronary
OCT images.
Intracoronary TD-OCT in swine in vivo was per-
formed in 2000 (77). This initial proof-of-concept
study demonstrated that TD-OCT provided images
of superior resolution when compared to IVUS and
allowed visualization of features not seen by ultra-
sound, such as the intima, including intimal flaps and
defects, disruptions in the media, and stent strut
apposition. This study was soon followed by first-in-
Figure 3. OCT Images and Corresponding Histology
Optical coherence tomography (OCT) images and corresponding hi
(E, F) lipid-rich plaque type. In ﬁbrous plaques (A, B), the optical co
homogenous. In comparison, both calciﬁc regions (arrows) (C, D) a
vessel wall. Lipid-rich plaques have diffuse or poorly demarcated bo
(B, D, hematoxylin and eosin; F, Masson’s trichrome; original magni
branch. Reprinted with permission from Tearney et al. (25).
Figure 4. Classiﬁcation of Sirolimus-Eluting Stent Strut Conditio
(A) Well-apposed with neointimal coverage (arrows). (B) Well-appo
neointimal coverage (arrows). OCT  optical coherence tomography. Rhuman demonstrations in 2002 (73,74,78,79). In the
years since this initial demonstration, TD-OCT has
been used extensively by a number of investigators in
the clinical realm for assessing coronary plaque fea-
tures (80–84), stent placement (26–28,85), apposi-
tion (26,29–31,85), stent strut coverage (32–36,85)
(Fig. 4), and thrombus (86), As for most catheter-
based optical imaging modalities, it is necessary to
clear blood from the imaging field of view to obtain
information on the artery wall because blood scatters
and attenuates light. Intracoronary OCT has been
gy for (A, B) ﬁbrous plaque type, (C, D) calciﬁc plaque type, and
nce tomography (OCT) signal (Fib) is observed to be strong and
ipid-rich regions (L) (E, F) appear as signal-poor regions within the
rs whereas the borders of calciﬁc nodules are sharply delineated.
ion 40.) Scale bars, tick marks  500 m. *Indicates a side
y OCT
without neointimal coverage (arrows). (C) Malapposed withoutstolo
here
nd l
rde
ﬁcatns b
sed
eprinted with permission from Matsumoto et al. (85).
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1027successfully demonstrated in vivo using either a flush
with an optically transparent media such as saline or
radiocontrast, or combined flushing with proximal
balloon occlusion. While effective for displacing
blood, the nonocclusive method only provides a
limited view of the vessel, containing few images,
and balloon occlusion may be associated with myo-
cardial ischemia and chest pain during the proce-
dure (87,88).
Second-generation OCT has, to a large part,
solved the blood limitations of TD-OCT. In 2003,
FD-OCT/OFDI (64,65,89) was shown to have a
sensitivity advantage over TD-OCT. This realiza-
tion led to the development of second-generation
intracoronary OCT systems that perform OCT
imaging at significantly higher frame rates than
TD-OCT, but with superior image quality (66).
When used in conjunction with a saline/radiocontrast
flush and rapid helical pullback scanning of the
catheter (67,90), FD-OCT/OFDI makes it practi-
cal to conduct 3-dimensional OCT imaging of long
coronary artery segments without balloon occlusion
(67,90). The fast pullback rate (10 to 20 mm per
second) allows the injection of only a small amount
of contrast media to clear the artery, therefore
greatly reducing the risk of ischemia. Intracoronary
OFDI was first demonstrated in vivo in swine
studies in 2006, in human patients in 2008 (Fig. 5)
(90), and is now poised to become a widely used
imaging modality in interventional cardiology with
many centers now publishing results from on-going
clinical studies (91–96). In fact, intracoronary TD-
OCT has been performed on thousands of coronary
patients at several hundred sites around the world
and, with the recent FDA approval of intracoronary
FD-OCT systems in the United States, it is antic-
ipated that these numbers will greatly increase. The
use of intravascular OCT to date has been primarily
investigational, and therefore its clinical use warrants
further exploration. Despite the greatly improved
resolution compared to IVUS, the penetration depth
of OCT is limited in lipid-containing plaque, and
therefore, the full thickness of the artery wall may, in
some cases, not be visible. As a result, certain mea-
surements that require visualization of the external
elastic membrane, such as plaque burden, cannot be
reliably performed with OCT. Despite this limitation,
it is expected that OCT use will increase and will
complement or even replace IVUS for many clinical
applications, including thrombus and superficial
plaque characterization, evaluating the results of stent
placement, lesion coverage, apposition of stent struts
to the vessel wall, and edge dissections.PS-OCT
PS-OCT is an extension to OCT technology that
provides a quantitative measure of a property of tissue
called birefringence, which alters the polarization of
light and is correlated to proteins and macromolecules
with oriented structure, such as collagen and actin
(97–99). In 2006, a quantitative study examining
utility of PS-OCT to measure tissue birefringence of
aortic plaques was performed by Nadkarni et al. (37).
The study revealed that increased PS-OCT birefrin-
gence was correlated to abundant thick collagen fibers
and/or the presence of intimal SMC, suggesting that
the detection of high birefringence in PS-OCT im-
Figure 5. OFDI Images Obtained From Right Coronary Artery of
Immediately After Deployment of DES
The 3.0 cm optical frequency domain imaging (OFDI) pullback was
ing a lactated Ringers’ solution ﬂush at 3.0 ml/s. Images were acqu
frames/s, with a pullback speed of 5.0 mm/s, resulting in an image-
of 50 m. (A) A left anterior oblique angiogram after drug-eluting
deployment shows stent site (s) (blue arrow) and 3.0 cm OFDI pull
(ps) (red arrow). (B) Fly-through view (distal-proximal) demonstrate
lesion underneath the stent (arrow). (C) An OFDI cross-sectional im
at the location of yellow arrow in B, shows a large calciﬁc (Ca) nod
11-o’clock to 4-o’clock. (D) Perspective cutaway view of entire 3-d
volume-rendered OFDI data set (left is proximal; right is distal), dem
the stent (blue), a side branch (yellow arrow), and a large calciﬁc n
arrowhead). (E) Longitudinal section through a portion of the data
sponding to the gray dotted rectangle in D. The side branch (blac
calciﬁc nodule (red arrow) are evident. Scale bar and tick marks repa Patient
obtained dur-
ired at 100
to-image pitch
stent (DES)
back segment
s a calciﬁed
age, obtained
ule from
imensional
onstrating
odule (red
set, corre-
k arrow) and
resent 1 mm.Modiﬁed with permission from Tearney et al. (90).
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1028ages may imply increased plaque stability (Fig. 6).
Additional ex vivo studies have been reported dem-
onstrating the potential of PS-OCT for the assess-
ment of plaque collagen (100) and for distinguishing
between normal intima, fibrous, lipid-rich, and calcific
plaques (101). While promising ex vivo imaging
results have been reported, the translation of this
technology to the clinical setting for evaluating coro-
nary arteries has been slow due to technical challenges,
specifically in maintaining the polarization state of the
light as it travels through the rapidly rotating cathe-
ters. Recently, however, a number of solutions to this
dilemma were introduced (102–105), and in 2008, ex
vivo results from a catheter-based intracoronary PS-
OFDI system with frequency multiplexing were re-
ported (106). If successful, PS-OFDI may provide
additional information regarding the structural integ-
rity of the coronary artery and associated plaques that
cannot be inferred from standard OCT images alone.
Pilot studies investigating the usefulness of PS-OFDI
in patients are currently underway (107), and given
that the addition of PS capabilities does not change
the standard approach for conducting intracoronary
OFDI, it is reasonable to presume that, if clinically
useful, PS detection may be a feature incorporated
into future commercially available intracoronary OCT
systems.
Laser Speckle Imaging
Laser Speckle Imaging (LSI) measures the biome-
chanical properties of atherosclerotic plaques by
Figure 6. OCT Images and Corresponding Histopathology Demo
(A and E) Optical coherence tomography (OCT) images of ﬁbrous p
in A showing high birefringence as seen by the rapid transition of
retardation. (C) Picrosirius red stained histology section showing or
and H) Trichrome stained histology images. (F) PS-OCT image of ﬁb
gence below the luminal surface. (G) Corresponding picrosirius red
under polarized light microscopy. Scale bars  500 m. Reprinted withevaluating time-varying laser speckle patterns (Fig.
1). When a scattering medium such as tissue is
imaged using temporally coherent light from a laser,
a granular pattern of multiple bright and dark spots,
known as speckle, becomes apparent in the image as
a result of the interference of photons returning
from different regions within the tissue. In tissue,
the Brownian motion of endogenous light scatter-
ing particles causes scatter locations and optical
path lengths to dynamically change, resulting in
time-dependent intensity modulations of the laser
speckle. The rate of laser speckle modulation is
highly dependent on the motion of endogenous
scatterers, which is in turn influenced by the vis-
coelasticity of the medium (108).
Using these principles, a study conducted on ex
vivo arteries has demonstrated that the measure-
ment of the decorrelation time constant of intensity
modulations of time-varying laser speckle patterns
provides a method for characterizing atherosclerotic
plaques and for detecting unstable necrotic core
plaques with a sensitivity of 100% and a specificity
of 93% (Fig. 7) (38). By combining the analysis of
spatial and temporal information from laser speckle
patterns, it has been demonstrated that LSI may
additionally provide a measure of plaque fibrous cap
thickness (109). A recent study has shown that LSI
can be conducted through small diameter optical
fiber bundles, allowing the opportunity to conduct
intracoronary LSI through miniaturized intravascu-
lar catheters (110). At present, however, a clinically
viable LSI system has yet to be developed and
rating Collagen Birefringence In Atherosclerotic Plaques
es. (B) Polarization sensitive (PS)-OCT image of the ﬁbrous plaque
image from black to white, corresponding to 0° to 180° phase
e-red ﬁbers (thicker ﬁbers) under polarized light microscopy. (D
s plaque showing black region corresponding to low birefrin-
ned histology section showing yellow-green ﬁbers (thinner ﬁbers)nst
laqu
the
ang
rou
staipermission from Nadkarni et al. (37).
reg
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1029tested, although active research and development in
this area is ongoing. If successfully translated into
the clinical realm, the intracoronary LSI technique
offers the possibility of obtaining a measure of the
biomechanical properties of coronary plaques, a
feature that is currently not measured with other
intravascular optical imaging modalities.
Near-Infrared Spectroscopy
Spectroscopy is the study of the electromagnetic
spectrum when light interacts with molecules. In-
tracoronary diffuse reflectance near-infrared spec-
troscopy (NIRS) is conducted by evaluating the
absorbance of light at different wavelengths in the
near-infrared spectrum (1,000 to 2,400 nm), as-
sessed by measuring the amount of light remitted
from the vessel wall (Fig. 1). Because NIRS is a
diffuse technique and the absorption is accumulated
as the light scatters throughout the tissue, the
detected absorption spectra necessitate the use of
computational algorithms (“chemometrics”) to ex-
tract the desired chemical information. In 1993,
NIRS was first used to assess the atherosclerotic
plaque in the hypercholesterolemic rabbit aorta
(111), and after this initial demonstration, a num-
ber of groups have reported on the use of NIRS for
the assessment of the human arterial wall in ex vivo
autopsy studies (Fig. 8) (39,112–114). However, it
was not until 2002 that Moreno et al. (114) dem-
onstrated the ability of NIRS to detect many of the
typical hallmarks of the unstable plaque including
lipid pools (90% sensitivity, 93% specificity), thin
fibrous caps (77% sensitivity, 93% specificity), and
inflammatory cells (84% sensitivity, 91% specific-
Figure 7. Cross Pathology Photograph and Spatial Distribution
(A) A cross pathology photograph of a lipid-rich plaque and (B) the
time constant (scale: black  400 ms, red  30 ms). The plaque bo
tion to regions that correspond to a reduction in cap thickness (redity). That study provided the necessary support forthe continued development of a clinically viable
intracoronary NIRS system. Miniaturized intra-
coronary catheters for NIR spectroscopy were con-
structed (115,116), and the first demonstration of
intracoronary NIRS in patients was reported in
2006 (117,118).
After these initial pre-clinical– and clinical-proof
of principle demonstrations, a more comprehensive
validation study of intracoronary NIRS was pub-
lished in 2009 by Waxman et al. (119) in 106
patients. The goal of the study was to compare the
NIRS spectra obtained in vivo to spectra previously
obtained and validated by histology in autopsy
specimens, which was found to be similar in 83% of
cases in which adequate spectra were obtained (95%
confidence interval: 70% to 93%). The mean pull-
back length over which spectra was obtained was
54.4  22.8 mm, and imaging was performed at a
rate of 0.5 mm/s (119). This study demonstrated
that NIRS can be safely and successfully performed
in living patients for the detection of lipid-
containing coronary plaques, through blood and in
the presence of cardiac motion. An important
advantage of this technique, as it is implemented
clinically, is that the NIRS signature can be trans-
mitted through whole blood, and as a result does
not require removal of blood from the artery lumen.
The LipiScan system (InfraReDx, Burlington,
Massachusetts) was recently approved by the FDA
for human coronary use. NIRS has additionally
been incorporated into a dual functioning catheter
that provides simultaneous IVUS and NIRS imag-
ing with an automated longitudinal pullback of 0.5
mm/s, with 360° vessel imaging (120). The intro-
duction of these catheters into the coronary artery
responding spatial distribution map of the speckle decorrelation
rs are clearly visualized in the speckle decorrelation map in addi-
ions). Reprinted with permission from Nadkarni et al. (38).Map
cor
rdecan be performed with ease, and imaging may be
olds
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1030conducted over long arterial segments including
relatively distal segments.
Initial studies have demonstrated the diagnostic
potential of this imaging modality (117–119,121),
including the identification of lipid pool plaques
that may be at higher risk for plaque rupture and
the development of acute coronary syndromes. Fur-
thermore, it has been hypothesized that large lipid
pool plaques can be associated with increased rates
of periprocedural complications, like increased rates
of myocardial injury, marker elevations, side-branch
obstruction, and distal embolization of the lipid
pool that may result in the so-called slow/no-flow
phenomenon (121). The COLOR (Chemometric
Observations of Lipid Core Plaque of Interest in
Native Coronary Arteries) registry is currently eval-
uating the long-term significance of lipid-core
plaques that are detected with the LipiScan system
in 1,000 patients. This study will no doubt help to
understand the clinical significance of these NIRS-
enabled findings. In addition, studies are being
conducted to understand the risk of embolization
and side-brunch compromise by large lipid-
containing plaques. With expanding clinical expe-
rience and research, NIRS may play a key future
role in improving diagnosis and treatment of pa-
Figure 8. Circumferential Lipid-Core Plaque Histopathologic-Che
(C) Near-infrared spectroscopy (NIRS) image of a large circumferent
mm); rotation (y-axis). (A, B) Histological correlates from the locatio
the presence of (A) the large lipid-core with numerous cholesterol
tal edge of the lipid-core plaque. Reprinted with permission from Gtients with coronary artery disease.Raman Spectroscopy
Raman spectroscopy (400 to 2,000 cm1)
(122,123), including high wavenumber Raman
spectroscopy (2,400 to 3,800 cm1) (124), is
another method that provides a quantitative mea-
sure of the chemical composition of biological
tissues. When light is incident on tissue, the ma-
jority of photons that collide with molecules will
scatter with the same frequency and wavelength as
the incident photons. A small portion of the inci-
dent photons may, however, be scattered with a
different frequency as a consequence of an energy
exchange between the molecule and colliding pho-
ton (Raman scattering) (Fig. 1). This change in
energy is equal to the differences of the vibrational
and rotational energy levels of the molecule and is
unique to specific chemical compounds. Therefore,
by measuring and performing comparative analyses
of the Raman spectra of the arterial tissue of interest
against Raman spectra of known chemical constit-
uents commonly found in arterial tissues, the rela-
tive chemical composition of the tissue can be
determined.
Raman spectroscopy has been shown to provide a
highly specific detection of chemical constituents
graphic Correlates
pid-core plaque (yellow) imaged post-mortem. Pullback (x-axis,
ndicated by the solid arrow and dashed arrow in C, conﬁrming
tals (arrow), and (B) an intracoronary thrombus (arrow) at the dis-
tein et al. (121).mo
ial li
ns i
cryssuch as elastin, collagen, cholesterol, cholesterol
a
t
t
w
ing
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1031esters, triglycerides, phospholipids, and calcium
salts and has been successfully utilized for the
chemical analysis of human atherosclerotic plaques
(122,123,125–128) (Fig. 9). Used in conjunction
with optical catheters designed with independent
illumination and collection fibers (127,129,130),
Raman spectroscopy has been demonstrated in vivo
for the analysis of the femoral and carotid artery,
and the aortic arch in sheep (131), of carotid
plaques in patients (128,130), and ex vivo for
interrogating coronary artery segments obtained
from autopsy samples (127,132). Although first
demonstrated in 1992, Raman spectroscopy has not
progressed toward a clinically viable intracoronary
imaging technology as rapidly as other optical
imaging techniques such as OCT. That may be in
part due to the very low intensity of the Raman
spectra detected from the tissue when implemented
in fiber-based imaging catheters. Catheter-based high-
wavenumber Raman spectroscopy systems are less
ffected by the noise generated in the fibers, and as
he development of high-wavenumber Raman spec-
roscopy is relatively new, it remains to be seen
hen this technology will be introduced clinically.
Fluorescence Spectroscopy
Fluorescence spectroscopy measures the short-
Figure 9. Chemical Concentrations Within a Human Coronary A
Raman Spectroscopy
(Upper Panel) The upper contour map shows the total cholesterol
lower graph displays the nonesteriﬁed-cholesterol to cholesterol es
estimated to be above 5% (gray otherwise). The plot abscissa indic
ﬁber sensor in the catheter is recording information along a given
centered 2.5 cm suggests the presence of a necrotic core containlived fluorescence that is emitted from a moleculeafter excitation by light. In early studies, diag-
nostic algorithms were developed by measuring
differences in tissue fluorescence spectra of colla-
gen, elastin, calcium and lipids, which were
demonstrated to broadly discriminated between
normal artery and atherosclerotic plaque with a
high sensitivity and specificity (133–135). To
further increase the specificity for the detection of
various constituents in atherosclerotic plaques
and for improved plaque characterization, the use
of time-resolved laser-induced fluorescence spec-
troscopy (TR-LIFS) was investigated. TR-LIFS
has been demonstrated using pulsed sampling
(337 nm, 700 ps pulse width) and gated detection
(136,137), resulting in an increased resolution of
the spectral overlap of individual chromophores
in plaques (138). Studies have demonstrated the
successful implementation of TR-LIFS for the ex
vivo characterization of atherosclerotic plaque
(139). Using this technique, macrophage foams
cells were detected with high sensitivity (85%)
and specificity (95%) in rabbit model in vivo
(140), and very recently, a study was reported
using TR-LIFS for the evaluation of carotid
artery lesions in patients by Marcu et al. (141).
This study demonstrated that TR-LIFS can be
used to classify tissues into 3 plaque categories
including intimal thickening, fibrotic and fibro-
y Determined Using Intravascular Catheter System Based on
centrations throughout the artery segment. (Lower Panel) The
FC/CE) ratio, calculated when the amount of total cholesterol was
the length along the sample, while the ordinate indicates which
The large increase in the FC content within the focal deposit
crystalline cholesterol. Figure courtesy of James Brennan.rter
con
ter (
ates
row.calcific plaques, and inflammation and necrotic
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1032lesions, and can additionally determine the
plaque biochemical content including elastin,
collagen, inflammatory cells, and necrosis (141).
Recent advancements in fluorescence spectros-
copy techniques have enhanced the potential
clinical utility of this optical diagnostic modality
by increasing the field of view facilitating
2-dimensional mapping of detected fluorophore
distributions (142). This new approach, termed
fluorescence lifetime imaging microscopy (FLIM),
utilizes a gated intensified charge coupled device
camera, a pulsed laser source (337 nm, 700 ps pulse
width), a fiber bundle/lens configuration for in-
creased field of view, and a filter wheel for selective
collection of emission wavelengths (143). Using this
system, the authors mapped the fluorescence life-
time of human aorta samples ex vivo and, although
preliminary, demonstrated a shift in the measured
lifetimes of elastin fluorescence emission in the
normal artery and collagen and lipid-rich regions in
the atherosclerotic artery (Fig. 10) consistent with
prior TR-LIFS studies (143). Fluorescence spec-
troscopy techniques, specifically TR-LIFS and
FLIM, have been demonstrated to provide infor-
mation on the biochemical composition of arterial
tissue and to differentiate between both normal and
atherosclerotic tissue regions of interest. Although
the results of this technology appear promising,
Figure 10. FLIM Images of Normal Artery
Fluorescence lifetime imaging microscopy (FLIM) images of normal
width) and (B) at 460/60 nm. Note the uniformly 2 ns average life
atherosclerotic artery (aorta) at (C) 377/50 nm and at (D) 460/60 nm
ﬂuorescence, and the shorter lifetimes in D, which is a character
collagen-rich areas (region-of-interest [ROI] 2) and lipid-rich area
respond to those images. Black line indicates ROI 1, blue line in
mission from Marcu (142).TR-LIFS and FLIM have yet to be incorporated
into clinical systems and catheters suitable for
human use.
Near-Infrared FluorescenceMolecular Imaging
Optical molecular imaging techniques enable the
visualization of molecules that have been labeled
with a fluorescent compound (Fig. 1). Recent ad-
vances in cardiovascular biology and biochemistry
and in optical imaging technologies, in particular
intravascular near-infrared fluorescence imaging
(NIRF) (40), have increased the potential for mo-
lecular imaging of atherosclerosis. Rather than op-
erating in the visible region, NIRF utilizes imaging
agents with emission wavelengths of between 650
nm and 1,000 nm. This shift in wavelength offers
advantages over conventional fluorescence imaging
techniques, including an increase in the penetration
depth due to a reduction in the photon absorption
from blood hemoglobin, lipid, and water, and a
reduction in the detected tissue autofluorescence,
leading to a significant increase in the signal-to-
noise ratio, or target-to-background ratio of the
NIRF imaging agents.
NIRF was recently demonstrated in human
carotid plaque specimens using a 1-dimensional
fiber-based catheter (144), and was subsequently
ry (thoracic aorta) (A) at 377/50 nm (center wavelength/band-
es, characteristics of elastin ﬂuorescence emission. Images of an
ote the longer lifetimes in C, which is a characteristic of collagen
of lipid ﬂuorescence, indicating that the plaque includes both
OI 1). Histograms depicted to the right of the FLIM images cor-
tes ROI 2, and green line indicates ROI 3. Reprinted with per-arte
tim
. N
istic
s (R
dica
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1033demonstrated in the iliac vessels of balloon-
injured, cholesterol-fed rabbits in vivo (Fig. 11)
(145–147). This study was conducted using a
protease-activatable NIRF imaging agent (Prosense750,
VisEn Medical, Woburn, Massachusetts) used to
detect cysteine protease enzyme activity in vivo
(148), and therefore, may provide insight to the
inflammatory pathways within atherosclerotic le-
sions. While a number of NIRF imaging agents
are currently in development and have been
demonstrated to enable visualization of atheroma
inflammation, calcification, and angiogenesis
(40), the results obtained with the NIRF catheter
demonstrate the significant potential for this
imaging technology. Although NIRF has great
potential for expanding our diagnostic capabili-
ties for coronary arteries, it is still in the early
stages of development. In addition to necessary
developments in the imaging technology, the
future clinical use of NIRF also requires the
development and regulatory approval of new-
targeted diagnostic imaging agents.
Figure 11. Real-Time Intravascular NIRF Imaging of Protease Ac
(A) The intravascular catheter was modiﬁed from a clinical optical c
imaging. Near-infrared ﬂuorescence (NIRF) (red) was emitted in a 9
atherosclerotic iliac arteries after balloon injury and hyperlipidemic
Prosense750 (VisEn Medical, Woburn, Massachusetts) injection, the N
(LIA) and then pulled back (dotted arrow) manually over 20 s. Ao 
NIRF showed signal peaks in areas of plaques but not in control se
in vivo imaging ﬁndings. (E) Merged 2-color ﬂuorescence microscop
was spatially distinct from 500 nm autoﬂuorescence (green). Modiﬁed wMultimodality Imaging
In many cases, the imaging technologies outlined
in this review provide complementary informa-
tion regarding coronary artery composition and
structure to other optical and nonoptical imaging
modalities. Therefore, the future of clinical in-
travascular imaging may lie in multimodality
imaging systems that combine 2 or more imaging
technologies to more comprehensively assess cor-
onary pathology. The fusion of optical imaging
technologies, while still in the early stages of
development, is currently the focus of many
leading research laboratories with investigators
conducting preliminary feasibility and proof-of-
principle studies evaluating complementary
coregistered imaging technologies and develop-
ing prototype hybrid systems and catheters. Ex-
amples of multimodality or hybrid systems in-
clude OCT and fluorescence spectroscopy (41),
combined reflectance, fluorescence, and Raman
spectroscopy (42), and OCT and FLIM (149);
while optical/nonoptical hybrid devices include
y
rence tomography guide wire used in human coronary artery
c and focused 2 mm away from the aperture. (B) Angiogram of
. White arrow indicates plaque. Twenty-four hours after
guide wire was placed percutaneously into the left iliac artery
rta; RIA  right iliac artery. (C) Real-time voltage recordings of
nts. (D) Ex vivo ﬂuorescence reﬂectance images corroborated the
f atheroma section demonstrated focal plaque NIRF (orange) thattivit
ohe
0° ar
diet
IRF
ao
gme
y oith permission from Jaffer et al. (147).
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1034OCT and positron detection (150), NIRS and
IVUS (151,152), and OCT and IVUS (153,154).
Arguably the most advanced clinical intravascular
multimodality optical/nonoptical imaging technol-
ogy is the NIRS-IVUS system by InfraReDx Inc.
that has recently received FDA approval for clinical
use (120). Although it is clear that large prospective
studies are required to further evaluate the clinical
utility of this technology, the first case studies
demonstrating the use in patients have recently
been published (151,152). The combined NIRS-
IVUS imaging system provides physicians with a
powerful tool to evaluate the structure of the coro-
nary artery using the IVUS technology, and to
provide an index of lipid content by NIRS. Al-
though similar information on coronary pathology
may be obtained using stand-alone IVUS and
NIRS imaging systems, the benefits of combining
multiple complementary imaging technologies into
single multimodal systems and catheters directly
translates to an increase in intracoronary informa-
tion without increasing coronary instrumentation,
catheterization times, the risk of complications, and
cost. In addition, the registration accuracy between
the imaging sets, and therefore the correct interpre-
tation of the coronary pathology, will undoubtedly
be increased in the multimodality systems. Given
the apparent need for multiple imaging technolo-
gies to more comprehensively assess the coronary
arteries, we will no doubt see a significant increase
in the number of hybrid multimodality imaging
systems that may include one or more optical
imaging techniques in the near future.
Conclusions
Table 1 summarizes many of the key characteristics
of the intravascular imaging modalities discussed in
Table 1. Summary of Many Key Features of Intravascular Optica
Measurement, Resolution, and Stage of Each Imaging Technolo
Technology Mechanism Measure
Angioscopy Superﬁcial imaging Surface structure
OCT/OFDI Backscattering Microstructure
PS-OCT Birefringence Collagen/SMC vs
LSI Speckle modulation Biomechanics
NIRS Absorption Composition lipid
Raman Inelastic scattering Composition lipid
TR-LIFS Autoﬂuorescence Composition
NIRF Fluorescence Molecular labels
*Indicates human xenograft.
FDA Food and Drug Administration; LSI laser speckle imaging; NIRF nea
tomography; OFDI optical frequency domain imaging; PS polarization sensi
spectroscopy.this review, including: 1) the optical mechanism
behind the imaging modality; 2) the arterial prop-
erties measured; 3) the resolution of the technology;
and 4) the current status of the technology in
relation to clinical translation and adoption.
Of the imaging modalities described, angioscopy,
NIRS, and OCT/OFDI are commercially available
and are approved for human use; however, it re-
mains to be determined what impact these imaging
modalities will have in clinical practice. LSI, fluo-
rescence spectroscopy, NIRF imaging, Raman
spectroscopy, and PS-OCT have yet to make the
successful transition to the clinical setting, and
many have technical hurdles remaining to be ad-
dressed before translation, including solving issues
such as the interference of the optical signal from
blood in the artery and motion artifacts. For wide-
spread adoption to occur, extensive safety, efficacy,
standardization, and validation are required of all
imaging techniques. OCT/OFDI has sufficient res-
olution to enable visualization of the majority of the
features associated with the vulnerable plaque; how-
ever, it does not provide the same biochemical
information available with NIRS or the biome-
chanical analyses from LSI. Likewise, OCT/OFDI
is the only modality that enables quantitative anal-
yses of stent placement, apposition and strut cover-
age, and could provide significant new insight into
mechanisms of stent healing of current and next
generation coronary stents. The future of intracoro-
nary optical imaging may, therefore, lie in a com-
bination of these complementary imaging modali-
ties producing a synergistic assessment of the artery
wall.
The ideal intracoronary optical imaging tech-
nique should be atraumatic, safe, and should facil-
itate rapid and systematic assessment of the entire
coronary arteries, with accurate detection and diag-
aging Modalities Discussed, Including Mechanism,
t Resolution Stage
position 100 m Commercial, FDA approved
10 m Commercial, FDA approved
d 10 m Pilot clinical studies
100 m Ex vivo
1 mm Commercial, FDA approved
1 mm Swine*
100 m Rabbit
100 m Rabbit
ared ﬂuorescence; NIRS near-infrared spectroscopy; OCT optical coherence
SMC smooth muscle cell; TR-LIFS time-resolved laser-induced ﬂuorescencel Im
gy
men
com
. lipi
r-infr
tive;
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1035nosis of coronary artery pathology, and should
additionally provide sufficient detail to facilitate
study of the evolution and etiology of the disease
process. Intravascular optical imaging of the coro-
nary arteries may provide a better assessment tool
for tailoring and monitoring pharmacological and
PCI interventions than the current standard of
care methods. Although there are currently no
proven therapies for reducing the risk of rupture
of the vulnerable plaque, optical imaging tech-
niques may additionally prove useful in furtheral. The role of shear stress in the based on a segdisease process through longitudinal imaging
studies.
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